Colorectal Cancer Screening Rates Surge Among 45-49 Year Olds Following USPSTF Guidelines

Colorectal cancer screening rates among commercially insured adults aged 45 to 49 in the United States surged following the U.S. Preventive Services Task Force’s May 2021 recommendation to lower the screening age from 50 to 45, according to an analysis of Blue Cross Blue Shield claims data through December 2022. The increase aimed to address rising early-onset colorectal cancer cases and was supported by a grade B recommendation ensuring insurance coverage without cost-sharing.

Screening rates for colorectal cancer among adults aged 45 to 49 with commercial insurance increased substantially after the U.S. Preventive Services Task Force (USPSTF) updated its guidelines in May 2021 to recommend routine screening beginning at age 45, according to an analysis of Blue Cross Blue Shield claims data. The USPSTF’s grade B recommendation expanded the eligible screening age range from 50-75 to 45-75 years to address rising cases of early-onset colorectal cancer, officials said.

Results showed a rapid increase in screening rates post-guideline, with an overall prevalence of 34.5% (95% confidence interval, 33.4%–35.8%) in 2022 for the 45-49 age group, according to the study.

A retrospective cohort study led by Siddique S. and colleagues, published October 3, 2024, in JAMA Network Open, reviewed deidentified claims from more than 10.2 million Blue Cross Blue Shield beneficiaries aged 45 to 49 between May 1, 2018, and December 31, 2022. The study compared screening uptake during the 20 months before the guideline change (May 2018–December 2019) with the 20 months after (May 2021–December 2022).

The increase was most pronounced in higher socioeconomic status (SES) areas and metropolitan regions, with screening rates rising by 0.24 percentage points every two months in high SES areas and 0.20 points in metropolitan areas, researchers reported. This trend was supported by a facility-based study conducted by Vizient and Northern Illinois University, which found a 948% increase in monthly screening volume among 45- to 49-year-olds, compared to a 46% increase in the 50-75 age group. The Vizient study analyzed data from over 1,000 hospitals nationwide, confirming widespread institutional adoption of the new guidelines.

Endoscopic screening methods were the most commonly used among the younger cohort, accounting for 74.9% of screenings. Stool-based tests such as fecal immunochemical tests (FIT), high-sensitivity guaiac fecal occult blood tests (HSgFOBT), and stool DNA-FIT comprised 9.3%, while CT colonography was rare at 0.5%, according to a 2022 prevalence study that incorporated healthcare provider supply and CT colonography data. The USPSTF recommends several screening options for average-risk adults, including annual FIT, colonoscopy every 10 years, and sigmoidoscopy every 5 to 10 years combined with FIT, officials noted.

The grade B USPSTF recommendation ensures that private insurers provide coverage for colorectal cancer screening without cost-sharing under the Affordable Care Act (ACA), a factor that likely facilitated the surge in screening uptake. ACA provisions require no-cost coverage for preventive services with a USPSTF grade A or B recommendation, which took effect immediately for commercial plans after the May 2021 update. Prior to this change, screening typically began at age 50, despite a 15% increase in colorectal cancer incidence among adults aged 40 to 49 since 2000, according to health policy analyses.

Despite the increase, screening rates among 45- to 49-year-olds remain lower than those observed in older age groups. The 2022 Behavioral Risk Factor Surveillance System (BRFSS) data showed a 59.1% screening prevalence in the 50-54 age group, compared to 34.5% for 45-49-year-olds. Researchers emphasized the need for further investigation into disparities in screening access, noting that uptake was faster in higher SES and metropolitan areas, potentially reflecting socioeconomic and geographic inequities.

The USPSTF guidelines apply to average-risk adults without symptoms, prior colorectal cancer or polyps, inflammatory bowel disease, or high-risk genetic syndromes such as Lynch syndrome or familial adenomatous polyposis (FAP). The recommendation is based on modeling studies that demonstrated a moderate net benefit for screening in the 45-49 age group, balancing benefits against potential harms.

Medicare coverage for colorectal cancer screening aligns with USPSTF recommendations for older adults, while private insurance coverage expanded in 2021 for the younger cohort. Before the guideline update, national screening rates hovered around 70% for adults aged 50 and older, but approximately 25% of eligible individuals had never been screened as of 2016, according to prior public health reports.

Ongoing monitoring of screening trends and disparities will be essential to assess the long-term impact of the guideline change. Researchers from Blue Cross Blue Shield and collaborating institutions have called for further studies to evaluate equity in access and outcomes following the expanded screening age recommendation.